Abstract
This chapter covers changes related to the optic disc and abnormalities in various ocular conditions. This chapter is divided into the following sections. (1) Glaucoma, the most important section of this chapter, describes different changes that can be detected in glaucoma and important considerations in the interpretation of the retinal nerve fiber layer (RNFL) thickness profile. OCT can assess glaucoma using parameters: (a) peripapillary RNFL (retinal nerve fiber layer) parameters, (b) optic nerve head parameters, (c) macular parameters. Pitfalls and artifacts in image acquisition and interpretation are fully discussed. (2) The myelinated nerve fiber layer in the optic disc area and other parts of the retina. In OCT, because the myelinated sheet of nerves can reflect light almost completely, we always have a highly reflective surface with strong shadowing of the underlying tissue. (3) The optic pit and its secondary retinoschisis. OCT in optic pit maculopathy demonstrates a combination of outer retinal layer detachment and retinoschisis in most cases. (4) Anterior ischemic optic neuropathy (AION). In early-stage AION, OCT shows a considerable increase in RNFL thickness that converts to a plateau and then atrophies in 6 months. (5) Optic disc drusen, which is a progressive disease; most cases lose the RNFL and show visual field defects in perimetry. “Lumpy-bumpy” internal reflectivity on OCT images strongly suggests drusen. (6) OCT in neurologic disease that covers new OCT findings in MS (multiple sclerosis), NMO (neuromyelitis optica), papillitis, papilledema, and intracranial lesion or tumor, and their effects on the retinal layer will completely be explained with other complementary tests and tips for differentiation between papilledema and papillitis.
Access provided by Autonomous University of Puebla. Download chapter PDF
Similar content being viewed by others
Keywords
- Retinal nerve fiber layer
- Multiple sclerosis
- Glaucoma
- Papillitis
- Papilledema
- Optic disc drusen
- Optic pit
- Neuromyelitis optica
6.1 Glaucoma
Glaucoma is the main cause of irreversible blindness worldwide. Intraocular pressure is the only modifiable risk factor. Early detection of glaucoma is vital for the preservation of vision because damages will be permanent if they occur. Usually, structural damages occur before the functional loss (pre-perimetric glaucoma). So, screening the suspected individuals with OCT can be a valuable option.
Spectral-domain optical coherence tomography (SD-OCT) is the most utilized test and many studies have assessed the accuracy and reproducibility of OCT in different commercial platforms. Most confounding factors perhaps lie in the variation of normal ocular structures that overlaps with glaucomatous changes.
The following parameters can be assessed by OCT [1]:
-
1.
Peripapillary retinal nerve fiber layer (Figs. 6.1, 6.2, 6.3, 6.4 and 6.5)
-
2.
Optic nerve head (Fig. 6.6)
- 3.
Average RNFL thickness is between 91 and 117 μm in various studies with various OCT apparatus [2,3,4,5,6,7,8,9,10]. Interocular symmetry is also important and means RNFL differences of more than 8.8 microns are highly suggestive ofabnormal conditions [11]. Thinning of RNFL is the hallmark of glaucoma. (Fig. 6.4).
The value of these tests has been evaluated by area under the curve (AUC), which is a measure of how well a parameter can distinguish between diseased and healthy groups. As the AUC value approaches 1, the power of a test for discriminating normal from abnormal increases.
In OCT, indentations (Fig. 6.5) maybe the sign of early damage, even if the mean thickness is in the normal range. Shin et al. [12, 13] described that RNFL volume deviation (i.e., estimated lost RNFL) has higher sensitivity, specificity, and AUC—compared to average RNFL thickness—for the early detection of glaucoma. Liu et al. [14] proved that nerve fiber layer loss in the contralateral normal eye (assessed by visual field and optic disc photography) of glaucomatous patients suggests that OCT is more sensitive than other methods for detecting early glaucoma.
Optic nerve head (ONH) parameters include rim area (RA), cup volume (CV), disc area (DA), average cup disc ratio (ACDR), and vertical cup disc ratio (VCDR). All these variables could be provided by Cirrus HD-OCT 5000. In Spectralis (Heidelberg Engineering, Heidelberg, Germany) different variables could be defined such as MRW (minimum rim width) that extends from BMO (Bruch’s membrane opening to the ILM (internal limiting membrane. (Fig. 6.6) the green arrow represents the MRW extending from the Bruch's membrane opening (BMO) to the ILM (middle panel).
Pitfalls in Using the Retinal Nerve Fiber Layer Profile
Similar to other imaging in medicine, RNFL thickness profile and other related image modalities have some pitfalls that we should always keep in our mind when we want to read these images (Figs. 6.14, 6.15, 6.16, 6.17, 6.18, 6.19, 6.20 and 6.21).
Many studies that mostly measured the optic disc parameters and peripapillary nerve fiber with Cirrus reported high AUC values [15]. A review study by Michelessi et al. [16], evaluated 106 studies, on the diagnostic ability of optic nerve head imaging by OCT, Heidelberg retina tomography (HRT), glaucoma diagnosis (GDx) scanning, and nerve fiber layer thickness measurements for glaucoma, the investigators concluded that using these modalities solely may be insufficient for detecting and monitoring glaucoma because of the overestimation of accuracy of each test and these tests have nearly the same amount of accuracy. Therefore, we strongly advise that clinicians should not rely solely on these tests for glaucoma detection and should perform further evaluations such as perimetry. Other tests should also be considered and suspected cases of glaucoma should be followed carefully and closely to avoid missing early glaucoma.
Glaucoma OCT Masquerading Etiologies
Some diseases could create NFL changes resembling glaucoma. The most common is an old retinal vascular obstruction. Inner layer chronic ischemia after vascular obstruction results in inner layer atrophy, including the NFL, that can cause changes similar to glaucoma. Anterior ischemic neuropathy (AION) is another etiology that can also cause NFL atrophy. Heavy retinal peripheral laser treatment (e.g., panretinal photocoagulation in diabetes) also may result in a thin NFL. Compressive lesions in the brain such as brain tumors, multiple sclerosis, chronic resolving papillitis, or papilledema can all result in an NFL thickness pattern that is similar to glaucoma.
6.2 Myelinated Nerve Fiber Layer
Myelinated retinal nerve fiber layer (MRNFL) is the presence of a myelinated sheet around the axons of the retinal ganglion cells beyond the lamina cribrosa. It has a gray to white appearance with feathery borders. In ophthalmoscopy, a MRNFL appears as a white discrete lesion with frayed borders. In the peripheral part, they appear feather-like. The prevalence of this abnormality is between 0.57 and 1% of the normal population [17,18,19]; it is bilateral in 7.7% of cases [17].
Most (66%) of the time, it is not continuous with the optic nerve head (mostly in the inferotemporal area). However, in 33% of cases, it ends at the optic nerve head (mostly the superior part) [17, 18]. Myelinated retinal nerve fiber layer is usually an incidental finding that is discovered during an eye examination with normal acuity. However, it sometimes can be a part of a syndrome that includes high myopia, amblyopia, and MRNFL [19]. The MRNFL lesion is static during a person’s lifetime and rarely changes.
In OCT, MRNFL always has a high reflective surface and causes strong shadowing on underlying tissues because the myelinated sheet of the nerve can reflect light almost completely (Figs. 6.22, 6.23, 6.24 and 6.25). If this lesion is adjacent to the optic nerve head, some cyst-like spaces can be found superficially on the myelinated area.
Visual field defects and decreased vision are also associated with this condition [20]. Red-free and infrared images will show the lesions with a white appearance because of the high lipid content of the affected area. In autofluorescence, a deep dark area can be found that is related to blockage of the detection of lipofuscin by the lipid layer over it [21].
6.3 Optic Pit
Optic pit anomaly, morning glory disc anomaly, and optic disc coloboma are among the different appearances of congenital optic disc closure anomalies [22]. Defect in the lamina cribrosa with herniation of the abnormal retina and connection to the subarachnoid space is the main etiology [23]. The incidence of an optic pit is 1/11000 [24]. There are no gender preferences in this condition and 15% of cases are affected bilaterally [25]. This is a sporadic anomaly but can run in families.
In ophthalmoscopy, it appears as a gray, oval, hole-shaped depression more often in the inferotemporal part of the optic disc [24, 26] (Figs. 6.26, 6.27, 6.28, 6.29, 6.30, 6.31, 6.32, 6.33, 6.34, 6.35, 6.36, 6.37, 6.38, 6.39 and 6.40). The optic pit may be asymptomatic and discovered during a routine ophthalmology examination or may be associated with a visual field defect, an enlarged blind spot, or paracentral arcuate scotoma [27, 28]. However, 25–75% of patients with optic disc pit eventually experience maculopathy in their third and fourth decade of life [25, 27, 29, 30].
There is no known predisposing factor for the initiation of maculopathy, except possibly posterior vitreous detachment [22, 24, 31]. Maculopathy is associated with intraretinal and subretinal fluid accumulation with vision equal to or less than 20/70 [24].
Optical coherence tomography (OCT) imaging in optic pit maculopathy demonstrates a combination of retinal detachment and retinoschisis in 79.17% of cases (Figs. 6.27, 6.28 and 6.29), only retinal detachment in 12.5% of cases, and only retinoschisis in 8.33% of cases (Figs. 6.33 and 6.34) [32]. An outer layer hole (between schisis and serous detachment) occurs in approximately 73% of cases with maculopathy. Schisis often involves multiple layers [32] (Figs. 6.35, 6.36, 6.37, 6.38, 6.39 and 6.40).
In some patients, the inner layers dissolve and are lost because of longstanding disease, and only small strands remain. It appears as a posterior retinal detachment, similar to the pattern that occurs in pathologic myopia. However, the existence of such strands could help in the differentiation.
6.4 Anterior Ischemic Optic Neuropathy
Anterior ischemic optic neuropathy is the result of complete or partial impairment of optic nerve head perfusion. In AION, early-stage OCT imaging shows a considerable increase in the NFL thickness, which then converts to a plateau, and finally atrophies in 6 months [33]. The NFL loss is very similar to that of glaucoma and sometimes it is very difficult to differentiate it from glaucoma. However, in non-arteritic AION (NAION) ganglion cell inner plexiform layer (GCIPL) is significantly thinner, compared to a glaucomatous patient (Figs. 6.41, 6.42, 6.43, 6.44, 6.45, 6.46 and 6.47) [34].
In NAION, focal loss volume (FLV) and global loss volume (GLV) of the ganglion cell layer in the macula are significant. These findings have a good reproducibility for detecting ganglion cell loss in cases of NAION [35]. Schuster et al. [36] showed that macular choroidal thickness in both eyes of individuals affected with unilateral NAION is significantly lower than in normal individuals.
6.5 Optic Disc Drusen
Optic disc drusen or optic nerve head drusen (ONHD) may be caused by the accumulation of mucoprotein and mucopolysaccharides in the optic disc with progressive calcification. They are a benign congenital anomaly of the optic disc [37, 38]. The incidence of ONHD is 2.4% with 13% of cases occurring bilaterality [37] with an autosomal dominant inheritance pattern [39]. This finding may result from abnormal axonal metabolism that eventually leads to intracellular mitochondrial calcification [40]. With aging and atrophy of the axons overlying the drusen, they become more visible in an eye examination [41]. Optic nerve head drusen is a progressive disease and most patients lose the NFL and show visual field defects in the perimetry. Buried disc drusen can sometimes be difficult to differentiate from papilledema. In such cases, OCT can be helpful. Internal reflectivity that appears “lumpy-bumpy” on OCT images strongly suggests drusen; by contrast, the inner part of elevated papilledema is a smooth hyporeflective space [42]. Increased subretinal hyporeflective space (SHYPS) measurements along the RNFL thickness curve can also help differentiate between these two conditions; papilledema has a considerable increase [42]. Transient deflection of the peripapillary RPE also can be seen in intracranial pressure rise and may also be a good differentiating sign [43, 44].
Fundus autofluorescence (FAF) imaging is another modality that can help in diagnosing ONHD (Figs. 6.48, 6.49, 6.50 and 6.51). Hyperautofluorescence of the optic disc is diagnostic for ONHD, whereas papilledema will have increased papillary hypoautofluorescent areas. B-scan ultrasonography is the best method for differentiating and diagnosing buried drusen [45, 46].
6.6 OCT in Neurologic Disease
There are many recent studies about the role of OCT in the diagnosis, management, and monitoring of the treatment of patients with neurologic diseases. OCT clearly illustrates the nerve fiber layer without a myelin sheet and perhaps can provide a crystal clear sample of brain nerve fiber condition, therefore we can use it as a biomarker in diagnosing and treating neurodegenerative disease. Besides its value for diagnosis and management of neurological disease OCT is a noninvasive, noncontact, fast, safe, and reproducible imaging tool that provides information on neural tissue in vivo that reflects the condition of neuronal tissue in the brain.
How a neurologist could use and read OCT: The basics and retinal anatomy were discussed widely in the introduction section, but the most important parts of concern for neurologists are the macular area and retinal nerve fiber layer profile.
Multiple sclerosis (MS):
Optical coherence tomography has given greater comprehensions into the pathophysiology of MS. It is quick, non-invasive, and easy to use. The images are highly reproducible with high resolution. Evaluation of the RNFL and GCL using OCT hypothetically allows us to assess neuronal and axonal degeneration. OCT act as a window through that we can see central nervous system axonal health without a myelin sheet. OCT has established very practical concerns for research, predicting disability, and disease monitoring in MS. 90% of MS patients even who have not experienced optic neuritis (ON), will most likely also have lesions in their visual pathways [47, 48].
Recent studies are proved that RNFL and GCIPL thinning correlates with parameters such as biomarkers, visual disability, function, and MRI (magnetic resonance imaging) in MS. OCT parameters may also be able to calculate disability progress and visual function in MS.
The pathological mechanism of reduction of RNFL and ganglion cell and inner plexiform layer (GCIPL) thickness in MS patients despite a negative or positive history of prior ON is still in debate. Axonal retrograde degenerations in patients with the history of ON could explain the RNFL and GCIPL thinning (Figs. 6.52, 6.53, 6.54, 6.55, 6.56, 6.57 and 6.58). However, in MS patients without any history of ON about 6.73 μm reduction in RNFL and GCIPL have been reported [49].
With the evaluation of inter-eye percentage difference (IEPD), using OCT we can also differentiate MS patients from healthy controls [50]. The diagnostic accuracy of the IEPD (AUC) is 0.75–0.94 for the GCIPL and 0.73–0.86 for the RNFL with the diagnostic specificity of 97% of the GCIPL IEPD and sensitivity of 70% for discriminating healthy controls from MS with unilateral ON. The IEDP has possible to be a very useful paraclinical parameter because it is not affected using different devices, segmentation algorithms, intrapersonal factors, ethnicity, and physiological variability.
Neuromyelitis optica (NMO):
Neuromyelitis optica spectrum disorders (NMOSD) are relapsing autoimmune central nervous system (CNS) inflammatory conditions [51]. Longitudinally extensive transverse myelitis (LETM), optic neuritis (ON), and brain stem encephalitis are clinical hallmarks of this disease [52,53,54,55,56]. Depression [57], neuropathic pain [56] and fatigue [58] are important symptoms, Aquaporin-4 (AQP4-ab), a serum autoantibody against the astrocytic water channel is measurable in almost 80% of the patients [59,60,61,62]. NMOSD has different immunopathogenesis from MS, which powerfully determines both of these conditions as unattached neurologic entities [63,64,65] with different treatment modalities.
In 55% of the patient with NMOD, ON is the first clinical feature that usually results in severe structural destruction to the optic nerve and retina [66]. The disease pattern is bilateral, occasionally simultaneous ON, recurrent relapses, and severely disturbed visual acuity or even complete vision loss [66]. The disease progresses as subacute visual loss in days or weeks, with possible recovery in half a year [67, 68].
In the acute phase, OCT shows a highly swollen RNFL and near normal or mild thickening of GCIPL that are due to inflammatory processes. After the acute phase, the loss of retinal axons and ganglion cells happens over an era of 6 months [69, 70]. In NMOSD the optic nerve is frequently involved near the chiasm, therefore it can have an impact on the contralateral optic nerve even after a unilateral attack (Figs. 6.59, 6.60, 6.61, 6.62, 6.63 and 6.64).
NMOSD often results in severe RNFL thinning, especially after recurrent attacks, with RNFL thickness less than 30 μm [71]. Due to flooring effects after severe optic atrophy, the further neuro-axonal loss is difficult to monitor.
In MS retinal and GCIPL damage show a temporal preponderance, while in NMOSD all areas can be affected equally [70, 72]. After ON attack, reduced RNFL and GCIPL thickness are highly correlated with contrast visual acuity disturbance. [73, 74].
After ON about 20% of patients show microcystic changes in the inner nuclear layer (INL). References [75,76,77,78] called microcystic macular edema (MME) (Fig. 6.65).
MME is related to severe and fast axonal loss conditions due to various etiologies and is not specific to NMOSD [76, 79, 80].
Mueller cells are astrocytic cells mainly located on INL and are responsible for energy metabolism, water homeostasis, and neurotransmitter recycling and maybe the targeting for Aquaporin-4 that results in primary retinopathy in NMOSD [81,82,83].
In NMOSD without ON we can have neuroaxonal damage but in a limited amount [84].
The patient in Figs. 6.59, 6.60 and 6.61 was not diagnosed as NMO and was treated with a high dose of oral steroids without any significant change in vision on the right side. After 2 months she referred us because of the drop in left side vision a few days before. Laboratory examination revealed AQP4-ab positive in serum and after neurologic consultation, NMOSD diagnosis was confirmed.
Papillitis and Papilledema
Papilledema defines as the thickening of the peripapillary nerve fiber layer due to increase intracranial pressure (Figs. 6.66, 6.67 and 6.68) or acute accelerated hypertension (Figs. 6.69, 6.70 and 6.71). Papillitis describes as the thickening of the peripapillary nerve fiber layer secondary to inflammation (Fig. 6.72). In some patients, differentiating papillitis from papilledema is very difficult because of their similar fundoscopic and OCT characteristics. Pseudo-papilledema defines as fundoscopic blurring and elevation of the optic disc without any pathology. Optic disc drusen and small optic disc and hyperopia could masquerade papilledema. By OCT we could differentiate pseudopapilledema from real papilledema. An increase in peripapillary RNFL thickness occurs in 43.3% of patients with papilledema versus 9.7% in patients with pseudopapilledema. Papilledema usually shows thicker NFL in all quadrants (Figs. 6.66 and 6.67) [42]. Nasal RNFL measurement had the highest diagnostic ability to differentiate papilledema from pseudopapilledema in one study [85]. Another factor is the measurement of the subretinal hyporeflective space (SHYPS) (Fig. 6.68) thickness, which is significantly greater in papilledema (Fig. 6.68) [42]. In the chronic phase of papilledema, sometimes there is only extreme thinning of the nerve fiber layer.
Toxic/metabolic/drug-induced optic neuropathy:
Toxic optic neuropathy is a set of medical conditions which can be described by visual loss secondary to optic nerve damage by a toxin. It is mostly diagnosed in late stages when recovery is not possible. Exposure to toxic elements can happen in work environment, with ingestion of substances or foods comprising a toxin, or systemic medications.
Toxic optic neuropathy is characterized by reduced color vision, papillomacular bundle atrophy, and central or cecocentral scotoma.
It starts as an insidious painless, bilateral, progressive, symmetrical visual loss with variable optic disk pallor [86, 87]. Color vision disturbance or dyschromatopsia is regularly the first symptom. the loss of color vision is disproportionate to the decline in visual acuity [88]. The pattern of visual loss typically involves a central or paracentral field of vision and extends toward the periphery at the end stages. Common etiologies of toxic neuropathy are Methanol, Ethylene glycol (the most prevalent), Chloroquine family drugs, antibiotics such as Chloramphenicol, antitubercular drugs like Isoniazid, Ethambutol, antiarrhythmics like Digitals and Amiodarone, anticancer agents, like as Vincristine and Methotrexate and finally heavy metals such as Leads and Mercury.
We introduce a patient with Imatinib toxic neuropathy, a rare complication.
Imatinib is a 2-phenyl amino pyrimidine derivative that acts as a tyrosine kinase enzyme inhibitor[89].
Imatinib is an encouraging treatment modality in patients affected by chronic myeloid leukemia (CML) and gastrointestinal stromal tumor (GIST) [90]. Imatinib side effects consist of edema, skin rash, and ocular side effects.
The most common ocular side effects of imatinib include periorbital edema and optic neuropathy has not been reported till now. But there is a case report of Dasatinib optic neuropathy which is in the family of Imatinib [91] (Figs. 6.73, 6.74, 6.75, 6.76 and 6.77).
After consultation with his oncologist, we decided to discontinue the drug for 3 months, without any further treatment for him.
Intracranial space-occupying lesion and compressive optic neuropathy:
In the case of nerve fiber layer thinning (Figs. 6.78, 6.79, 6.80, 6.81 and 6.82), clinicians should always consider intracranial etiologies.
In the case of nerve fiber layer thinning, especially on the temporal side in an OCT image, neurological evaluation should seriously be performed to rule out intracranial etiologies.
We introduce a 48 years old male with 20/20 vision with a chief complaint of diplopia who was referred to us from the strabismus clinic. He had a car accident a few month ago with severe head trauma and loss of consciousness for a few days and hospitalization (Figs. 6.83, 6.84, 6.85, 6.86 and 6.87).
References
Mwanza JC, Budenz DL. Optical coherence tomography platforms and parameters for glaucoma diagnosis and progression. Curr Opin Ophthalmol. 2016;27:102–10.
Appukuttan B, Giridhar A, Gopalakrishnan M, et al. Normative spectral domain optical coherence tomography data on macular and retinal nerve fibre layer thickness in Indians. Indian J Ophthalmol. 2014;2014(62):316–21.
Knight ORG, Girkin CA, Budenz DL, et al. Effect of race, age, and axial length on optic nerve head parameters and retinal nerve fiber layer thickness measured by Cirrus HD-OCT. Arch Ophthalmol. 2012;130(3):312.
Budenz DL, Anderson DR, Varma R, et al. Determinants of normal retinal nerve fiber layer thickness measured by stratus OCT. Ophthalmology. 2007;114(6):1046–52.
Tariq YM, Li H, Burlutsky G, et al. Retinal nerve fiber layer and optic disc measurements by spectral domain OCT: normative values and associations in young adults. 2012;26(12):1563–70
MashigeK P, Oduntan OA. Retinal nerve fibre layer thickness values and their associations with ocular and systemic parameters in Black South Africans. Afr Health Sci. 2017;16(4):1188.
Sani R, Abdu L, Pam V. Retinal nerve fiber layer thickness measurements of normal Northern Nigerian adults using optical coherence tomography. Ann Afr Med. 2016;15:52–7.
Manassakorn A, Nouri-Mahdavi K, Caprioli J. Comparison of retinal nerve fiber layer thickness and optic disk algorithms with optical coherence tomography to detect glaucoma. Am J Ophthalmol. 2006;141:105–15.
Bendschneider D, Tornow RP, Horn FK, et al. Retinal nerve fiber layer thickness in normals measured by spectral domain OCT. J Glaucoma. 2010;19:475–82.
Hirasawa H, Tomidokoro A, Araie M, et al. Peripapillary retinal nerve fiber layer thickness determined by spectral-domain optical coherence tomography in ophthalmologically normal eyes. Arch Ophthalmol. 2010;128:1420.
Mwanza J-C, Durbin MK, Budenz LB. Interocular symmetry in peripapillary retinal nerve fiber layer thickness measured with the cirrus HD-OCT in healthy eyes. Am J Ophthalmol. 2011;151:514–21.
Shin JW, Uhm KB, Seong M. Retinal nerve fiber layer defect volume deviation analysis using spectral-domain optical coherence tomography. Invest Ophthalmol Vis Sci. 2015;56:21–8.
Shin JW, Uhm KB, Seong M, Lee DE. Retinal nerve fiber layer volume measurements in healthy subjects using spectral domain optical coherence tomography. J Glaucoma. 2014;23:567–73.
Liu T, Tatham AJ, Gracitelli CP, Zangwill LM, Weinreb RN, Medeiros FA. Rates of retinal nerve fiber layer loss in contralateral eyes of glaucoma patients with unilateral progression by conventional methods. Ophthalmology. 2015;122:2243–51.
Bussel II, Wollstein G, Schuman JS. OCT for glaucoma diagnosis, screening and detection of glaucoma progression. Br J Ophthalmol. 2014;98 Suppl–2:ii15–9.
Michelessi M, Lucenteforte E, Oddone F, Brazzelli M, Parravano M, Franchi S, et al. Optic nerve head and fibre layer imaging for diagnosing glaucoma. Cochrane Database Syst Rev. 2015;(11):CD008803.
Straatsma BR, Foos RY, Heckenlively JR, Taylor GN. Myelinated retinal nerve fibers. Am J Ophthalmol. 1981;91:25–38.
Kodama T, Hayasaka S, Setogawa T. Myelinated retinal nerve fibers: prevalence, location and effect on visual acuity. Ophthalmologica. 1990;200:77–83.
Tarabishy AB, Alexandrou TJ, Traboulsi EI. Syndrome of myelinated retinal nerve fibers, myopia, and amblyopia: a review. Surv Ophthalmol. 2007;52:588–96.
Lam AK, Pang PC. The effect of myelination on perimetry and retinal nerve fibre analysis. Clin Exp Optom. 2000;83:4–11.
Shelton JB, Digre KB, Gilman J, et al. Characteristics of myelinated retinal nerve fiber layer in ophthalmic imaging: findings on autofluorescence, fluorescein angiographic, infrared, optical coherence tomographic, and red-free images. JAMA Ophthalmol. 2013;131:107–9.
Jain N, Johnson MW. Pathogenesis and treatment of maculopathy associated with cavitary optic disc anomalies. Am J Ophthalmol. 2014;158:423–35.
Ferry AP. Macular detachment associated with congenital pit of the optic nerve head. Pathologic findings in two cases simulating malignant melanoma of the choroid. Arch Ophthalmol. 1963;70:346–57.
Georgalas I, Ladas I, Georgopoulos G, et al. Optic disc pit: a review. Graefes Arch Clin Exp Ophthalmol. 2011;249:1113–22.
Brodsky MC. Congenital optic disk anomalies. Surv Ophthalmol. 1994;39:89–112.
Theodossiadis GP, Panopoulos M, Kollia AK, et al. Long-term study of patients with congenital pit of the optic nerve and persistent macular detachment. Acta Ophthalmol. 1992;70:495–505.
Brown GC, Shields JA, Goldberg RE. Congenital pits of the optic nerve head. II. Clinical studies in humans. Ophthalmology. 1980;87:51–65.
Shah SD, Yee KK, Fortun JA, et al. Optic disc pit maculopathy: a review and update on imaging and treatment. Int Ophthalmol Clin Spring. 2014;54:61–78.
Bonnet M. Serous macular detachment associated with optic nerve pits. Graefes Arch Clin Exp Ophthalmol. 1991;229:526–32.
Kranenburg EW. Crater-like holes in the optic disc and central serous retinopathy. Arch Ophthalmol. 1960;64:912–24.
Brockhurst RJ. Optic pits and posterior retinal detachment. Trans Am Ophthalmol Soc. 1975;73:264–91.
Sanghi G, Padhi TR, Warkad VU, et al. Optical coherence tomography findings and retinal changes after vitrectomy for optic disc pit maculopathy. Indian J Ophthalmol. 2014;62:287–90.
Contreras I, Noval S, Rebolleda G, et al. Follow-up of nonarteritic anterior ischemic optic neuropathy with optical coherence tomography. Ophthalmology. 2007;114:2338–44.
Fard MA, Afzali M, Abdi P, et al. Comparison of the pattern of macular ganglion cell-inner plexiform layer defect between ischemic optic neuropathy and open-angle glaucoma. Invest Ophthalmol Vis Sci. 2016;57:1011–6.
Gonul S, Koktekir BE, Bakbak B, et al. Comparison of the ganglion cell complex and retinal nerve fiber layer measurements using Fourier domain optical coherence tomography to detect ganglion cell loss in non arteritic anterior ischaemic optic neuropathy. Br J Ophthalmol. 2013;97:1045–50.
Schuster AK, Steinmetz P, Forster TM, et al. Choroidal thickness in nonarteritic anterior ischemic optic neuropathy. Am Ophthalmol. 2014;158:1342–7.
Friedman AH, Henkind P, Gartner S. Drusen of the optic disc. A histopathological study. Trans Ophthalmol Soc U K. 1975;95:4–9.
Golnik K. Congenital optic nerve anomalies. Curr Opin Ophthalmol. 1998;9:18–26.
Antcliff RJ, Spalton DJ. Are optic disc drusen inherited? Ophthalmology. 1999;106:1278–81.
Tso MO. Pathology and pathogenesis of drusen of the optic nervehead. Ophthalmology. 1981;88:1066–80.
Spencer TS, Katz BJ, Weber SW, Digre KB, et al. 2004;24:297–8.
Johnson LN, Diehl ML, Hamm CW, Sommerville DN, Petroski GF. Differentiating optic disc edema from optic nerve head drusen on optical coherence tomography. Arch Ophthalmol. 2009;127:45–9.
Kupersmith MJ, Sibony P, Mandel G, et al. Optical coherence tomography of the swollen optic nerve head: deformation of the peripapillary retinal pigment epithelium layer in papilledema. Invest Ophthalmol Vis Sci. 2011;52:6558–64.
Sibony P, Kupersmith MJ, Rohlf FJ. Shape analysis of the peripapillary RPE layer in papilledema and ischemic optic neuropathy. Invest Ophthalmol Vis Sci. 2011;52:7987–95.
Kurz-Levin MM, Landau K. A comparison of imaging techniques for diagnosing drusen of the optic nerve head. Arch Ophthalmol. 1999;117:1045–9.
Boldt HC, Byrne SF, DiBernardo C. Echographic evaluation of optic disc drusen. J Clin Neuroophthalmol. 1991;11:85–91.
Ikuta F, Zimmerman HM. Distribution of plaques in seventy autopsy cases of multiple sclerosis in the United States. Neurology. 1976;26(6 PT2):26–8.
Toussaint D, Périer O, Verstappen A, et al. Clinicopathological study of the visual pathways, eyes, and cerebral hemispheres in 32 cases of disseminated sclerosis. J Clin Neuroophthalmol. 1983;3:211–20.
Britze J, Pihl-Jensen G, Frederiksen JL. Retinal ganglion cell analysis in multiple sclerosis and optic neuritis: a systematic review and meta-analysis. J Neurol. 2017;264:1837–53.
Coric D, Balk LJ, Uitdehaag BMJ, et al. Diagnostic accuracy of optical coherence tomography inter-eye percentage difference for optic neuritis in multiple sclerosis. Eur J Neurol. 2017;24:1479–84.
Wildemann B, Jarius S, Paul F. Neuromyelitis optica. Nervenarzt. 2013;84(4):436–41.
Jarius S, Paul F, Franciotta D, et al. Mechanisms of disease: aquaporin-4 antibodies in neuromyelitis optica. Nat Clin Pract Neurol. 2008;4(4):202–14.
Jarius S, Wildemann B, Paul F. Neuromyelitis optica: clinical features, immunopathogenesis and treatment. Clin Exp Immunol. 2014;176(2):149–64.
Wingerchuk DM, Banwell B, Bennett JL, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015;85(2):177–89.
Kremer L, Mealy M, Jacob A, et al. Brainstem manifestations in neuromyelitis optica: a multicenter study of 258 patients. Mult Scler. 2014;20(7):843–7.
Zhao S, Mutch K, Elsone L, et al. Neuropathic pain in neuromyelitis optica affects activities of daily living and quality of life. Mult Scler. 2014;20(12):1658–61.
Chavarro VS, Mealy MA, Simpson A, et al. Insufficient treatment of severe depression in neuromyelitis optica spectrum disorder. Neurol Neuroimmunol Neuroinflamm. 2016;e286:3.
Chanson J-B, Zéphir H, Collongues N, et al. Evaluation of health-related quality of life, fatigue and depression in neuromyelitis optica. Eur J Neurol. 2011;18(6):836–41.
Metz I, Beißbarth T, Ellenberger D, et al. Serum peptide reactivities may distinguish neuromyelitis optica subgroups and multiple sclerosis. Neurol Neuroimmunol Neuroinflamm. 2016;e204:3.
Zekeridou A, Lennon VA. Aquaporin-4 autoimmunity. Neurol Neuroimmunol Neuroinflamm. 2015;2(4):e110.
Paul F, Jarius S, Aktas O, et al. Antibody to aquaporin 4 in the diagnosis of neuromyelitis optica. PLoS Med. 2007;e133:4.
Jarius S, Ruprecht K, Wildemann B, et al. Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: a multicentre study of 175 patients. J Neuroinflammation. 2012;9:14.
Bennett JL, O’Connor KC, Bar-Or A, et al. B lymphocytes in neuromyelitis optica. Neurol Neuroimmunol Neuroinflamm. 2015;e104:2.
Melamed E, Levy M, Waters PJ, et al. Update on biomarkers in neuromyelitis optica. Neurol Neuroimmunol Neuroinflamm. 2015;e134:2.
Takeshita Y, Obermeier B, Cotleur AC, et al. Effects of neuromyelitis optica-IgG at the blood-brain barrier in vitro. Neurol Neuroimmunol Neuroinflamm. 2017;e311:4.
Ramanathan S, Prelog K, Barnes EH, et al. Radiological differentiation of optic neuritis with myelin oligodendrocyte glycoprotein antibodies, aquaporin-4 antibodies, and multiple sclerosis. Mult Scler. 2016;22(4):470–82.
Sanchez-Dalmau B, Martinez-Lapiscina EH, Torres-Torres R, et al. Early retinal atrophy predicts long-term visual impairment after acute optic neuritis. Mult Scler. 2017;1352458517718628.
Balcer LJ. Clinical practice. Optic neuritis. N Engl J Med. 2006;354(12):1273–80.
Sotirchos ES, Saidha S, Byraiah G, et al. In vivo identification of morphologic retinal abnormalities in neuromyelitis optica. Neurology. 2013;80(15):1406–14.
Schneider E, Zimmermann H, Oberwahrenbrock T, et al. Optical coherence tomography reveals distinct patterns of retinal damage in neuromyelitis optica and multiple sclerosis. PLoS ONE. 2013;8(6):e66151.
Costello F. Optical coherence tomography in neuro-ophthalmology. Neurol Clin. 2017;35(1):153–63.
Bock M, Brandt AU, Dörr J, et al. Patterns of retinal nerve fiber layer loss in multiple sclerosis patients with or without optic neuritis and glaucoma patients. Clin Neurol Neurosurg. 2010;112(8):647–52.
Merle H, Olindo S, Jeannin S, et al. Treatment of optic neuritis by plasma exchange (add-on) in neuromyelitis optica. Arch Ophthalmol Chic Ill. 1960;2012(130):858–62.
Monteiro MLR, Fernandes DB, Apóstolos-Pereira SL, et al. Quantification of retinal neural loss in patients with neuromyelitis optica and multiple sclerosis with or without optic neuritis using Fourier-domain optical coherence tomography. Invest Ophthalmol Vis Sci. 2012;53(7):3959–66.
Sotirchos ES, Saidha S, Byraiah G, Mealy MA, Ibrahim MA, Sepah YJ, et al. In vivo identification of morphologic retinal abnormalities in neuromyelitis optica. Neurology. 2013;80(15):1406–14.
Kaufhold F, Zimmermann H, Schneider E, et al. Optic neuritis is associated with inner nuclear layer thickening and microcystic macular edema independently of multiple sclerosis. PLoS ONE. 2013;8(8):e71145.
Gelfand JM, Cree BA, Nolan R, et al. Microcystic inner nuclear layer abnormalities and neuromyelitis optica. JAMA Neurol. 2013;70(5):629–33.
Brandt AU, Oberwahrenbrock T, Kadas EM, et al. Dynamic formation of macular microcysts independent of vitreous traction changes. Neurology. 2014;83(1):73–7.
Balk LJ, Killestein J, Polman CH, et al. Microcystic macular oedema confirmed, but not specific for multiple sclerosis. Brain J. Neurol. 2012;135:e226. Return to ref 128 in article
Gelfand JM, Nolan R, Schwartz DM, et al. Microcystic macular oedema in multiple sclerosis is associated with disease severity. Brain J Neurol. 2012;135(6):1786–93.
Felix CM, Levin MH, Verkman AS. Complement-independent retinal pathology produced by intravitreal injection of neuromyelitis optica immunoglobulin G. J Neuroinflammation. 2016;13(1):275.
Reichenbach A, Bringmann A. Müller cells in the healthy and diseased retina. 1st ed. New York: Springer; 2010.
Reichenbach A, Bringmann A. New functions of Müller cells. Glia. 2013;61(5):651–78.
Tian D-C, Su L, Fan M, et al. Bidirectional degeneration in the visual pathway in neuromyelitis optica spectrum disorder (NMOSD). Mult Scler. 2017;1352458517727604.
Bassi ST, Mohana KP. Optical coherence tomography in papilledema and pseudopapilledema with and without optic nerve head drusen. Ind J Ophthalmol. 2014;62:1146–51.
Lessell S. Nutritional deficiency and toxic optic neuropathies. In: Albert DM, Jakobiec FA, editors. Principles and practice of ophthalmology. 2nd ed. Philadelphia: W.B. Saunders Company; 2000. p. 4169–76.
Phillips PH. Toxic and deficiency optic neuropathies. In: Miller NR, Newman NJ, Biousse V, Kerrison JB, editors. Walsh and Hoyt’s clinical neuro-ophthalmology. 6th ed. Baltimore, Maryland: Lippincott Williams.
Kerrison JB. Optic neuropathies caused by toxins and adverse drug reactions. Ophthalmol Clin North Am. 2004;17:481–8.
Nagar B, Bornmann WG, Pellicena P, et al. Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). Cancer Res. 2002;62:4236–43.
Buchdunger E, O’Reilly T, Wood J. Pharmacology of imatinib (STI571). Eur J Cancer. 2002;385:S28–36.
Monge KS, Gálvez-Ruiz A, Alvárez-Carrón A, et al. Optic neuropathy secondary to dasatinib in the treatment of a chronic myeloid leukemia case. Saudi J Ophthal. 29(3):227–31
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2022 The Author(s), under exclusive license to Springer Nature Switzerland AG
About this chapter
Cite this chapter
Hajizadeh, F., Tabatabaei, S.M. (2022). Circumpapillary Retinal Nerve Fiber Layer, Optic Nerve Head, and Related Structural Abnormalities. In: Hajizadeh, F. (eds) Atlas of Ocular Optical Coherence Tomography. Springer, Cham. https://doi.org/10.1007/978-3-031-07410-3_6
Download citation
DOI: https://doi.org/10.1007/978-3-031-07410-3_6
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-031-07409-7
Online ISBN: 978-3-031-07410-3
eBook Packages: MedicineMedicine (R0)